Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

PUBLICATION DATE

8 results
Display

A BDNF Val66Met Polymorphism and Ketamine-induced Rapid Antidepressant Action

Hashimoto

  • Clin Psychopharmacol Neurosci.
  • 2012 Apr;10(1):59-60.
No abstract available.
The Impact of Personality Traits on Emotional Responses to Interpersonal Stress

Joo HJ, Yeon B, Lee KU

  • Clin Psychopharmacol Neurosci.
  • 2012 Apr;10(1):54-58.
OBJECTIVE: The aim of the present study was to examine the impact of personality traits on emotional responses to interpersonal stress. METHODS: Thirty-two healthy college students (18 men, 14 women; age...
No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an Selective Serotonin Reuptake Inhibitor or Serotonin Norepinephrine Reuptake Inhibitor and the Brain-Derived Neurotrophic Factor (Val66Met) Polymorphism in Refracto

Yoshimura , Kishi T, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Katsuki A, Hayashi K, Iwata N, Nakamura J

  • Clin Psychopharmacol Neurosci.
  • 2012 Apr;10(1):49-53.
OBJECTIVE: This study examined the association between the brain-derived neurotrophic factor (BDNF) (Val66Met) polymorphism and the response to the addition of an atypical antipsychotic drug to a selective serotonin reuptake...
Long-term Escitalopram Treatment in Korean Patients with Panic Disorder: A Prospective, Naturalistic, Open-label, Multicenter Trial

Choi KW, Woo JM, Kim YR, Lee SH, Lee SY, Kim EJ, Chung SK, Kang EH, Lee JH, Yu BH

  • Clin Psychopharmacol Neurosci.
  • 2012 Apr;10(1):44-48.
OBJECTIVE: Panic disorder is characterized by recurrent panic attacks, persistent concerns about additional attacks, and worry about the implications of the attack or significant changes in behavior related to the...
In Vivo Evaluation of 11C-labeled Three Radioligands for Glycine Transporter 1 in the Mouse Brain

Zhang JC, Toyohara J, Wu J, Ishiwata K, Hashimoto

  • Clin Psychopharmacol Neurosci.
  • 2012 Apr;10(1):34-43.
OBJECTIVE: Glycine transporter 1 (GlyT-1) is one of the most attractive therapeutic targets for schizophrenia. There is great interest in developing radioligands for in vivo imaging of GlyT-1 in the...
Altered Neuronal Markers Following Treatment with Mood Stabilizer and Antipsychotic Drugs Indicate an Increased Likelihood of Neurotransmitter Release

Scarr E, Dean B

  • Clin Psychopharmacol Neurosci.
  • 2012 Apr;10(1):25-33.
OBJECTIVE: Given the ability of mood stabilizers and antipsychotics to promote cell proliferation, we wanted to determine the effects of these drugs on neuronal markers previously reported to be altered...
Diffusion Tensor Imaging Findings of White Matter Changes in First Episode Schizophrenia: A Systematic Review

Kuswanto C, Teh I, Lee TS, Sim K

  • Clin Psychopharmacol Neurosci.
  • 2012 Apr;10(1):13-24.
Earlier structural magnetic resonance imaging in schizophrenia have noted smaller white matter volumes in diverse brain regions and recent diffusion tensor imaging (DTI) studies have allowed better elucidation of changes...
Are Cardiometabolic and Endocrine Abnormalities Linked to Sleep Difficulties in Schizophrenia? A Hypothesis Driven Review

Robillard , Rogers NL, Whitwell B, Lambert T

  • Clin Psychopharmacol Neurosci.
  • 2012 Apr;10(1):1-12.
Schizophrenia is a psychiatric disorder that includes symptoms such as hallucinations, disordered thoughts, disorganized or catatonic behaviour, cognitive dysfunction and sleep-wake disturbance. In addition to these symptoms, cardiometabolic dysfunction is...

Go to Top

Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr